SCHEMBL6943899

SCHEMBL6943899

O=C(O)/C=C/Sc1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 2/20 0.47
PLIN1 O60240 1/20 0.47
PLIN5 Q00G26 1/20 0.47
ABHD5 Q8WTS1 1/20 0.47
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
NAPRT Q6XQN6 1/20 0.40
JUN P05412 1/20 0.39
DDAH1 O94760 1/20 0.39
NOS1 P29475 1/20 0.39
KDM6B O15054 2/20 0.38
KDM4A O75164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943902 1.00 ALDH1A1 (0.47) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL6664645 0.82 ALDH1A1 (0.42) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL6664649 0.82 ALDH1A1 (0.42) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL9330897 0.81 ALDH1A1 (0.68) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL600479 0.81 ALDH1A1 (0.68) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL600478 0.81 ALDH1A1 (0.68) ALDH1A1MAPTLMNANPSR1HTT
Water SCHEMBL9776229 0.79 ALDH1A1 (0.66) ALDH1A1MAPTLMNANPSR1HTT
Water SCHEMBL9776234 0.79 ALDH1A1 (0.66) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL6944659 0.76 ALDH1A1 (0.47) ALDH1A1MAPTLMNANPSR1HTT
SCHEMBL6944654 0.76 ALDH1A1 (0.47) ALDH1A1MAPTLMNANPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642246-B1 Potent ligands for nicotinic acetylcholine receptors (nAChRs). Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's ASTRAZENECA AB (SE) 2003-11-04 US disclosed
EP-1235826-B1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2003-09-03 EP disclosed
EP-1235826-A1 QUINUCLIDINE ACRYLAMIDES AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2001029034-A1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2001-04-26 WO disclosed